Dart Neuroscience, (cayman) Ltd.

Ligand Pharmaceuticals, Inc.

Dart Neuroscience, LLC

Andrew Richard Hudson

Lino J Valdez

Marco Peters

Lin Zhi

Jason Conrad Pickens

Yixing Shen

Steven L Roach

Laurent Gomez

Brian Dyck

James Breitenbucher

Bijan Pedram

Bryan James Branstetter

Troy Vickers

Tami Jo Marrone

Cornelis Arjan Van Oeveren

Jillian Basinger

Brett C Bookser

Michael I Weinhouse

Keith B Marschke

Virginia H Grant

Mi Chen

Benjamin Pratt

Virginia Heather Sharron Grant

Joe Anh Tran

Joel Renick

Pablo Garcia-Reynaga

Vincent Santora

James Na

Aaron Thompson

Scott Burley

Jillian Basinger Thompson

Alan P Kaplan

Varsha Gupta

DeMichael Chung

C Arjan Van Oeveren

Cornelius Arjan Van Oeveren

Catalina Cuervo

Virgina H Grant

Bryan Branstetter

Lino Valdez

Thompson Jillian Basinger

Joe Tran

Jason C Pickens

Substituted cyclohexyl chemical entities of Formula (I):

Substituted cyclohexyl compounds as NOP inhibitors

Some embodiments include compositions and methods of using or identifying compounds that modulate the activity of the granulocyte colony-stimulating factor receptor (GCFR). Some embodiments include use of compounds to treat certain disorders, such as hematopoietic or neurological disorders.

Methods and compositions associated with the granulocyte colony-stimulating factor receptor

Substituted cyclohexyl chemical entities of Formula (I): wherein R, G, and Rhave any of the values described herein, and compositions comprising such chemical entities; methods of making them; and their use in a wide range of methods, including metabolic and reaction kinetic studies; detection and imaging techniques; radioactive therapies; modulating and treating disorders mediated by nociceptin activity or dopamine signaling; treating neurological disorders, neurodegenerative diseases, depression, and schizophrenia; enhancing the efficiency of cognitive and motor training; and treating peripheral disorders, including renal, respiratory, gastrointestinal, liver, genitourinary, metabolic, and inflammatory disorders. 

Substituted cyclohexyl compounds as NOP inhibiiors

Described herein are compounds of Formula I and Formula II, methods of their synthesis, compositions comprising the compounds, and use of the compounds and compositions in treating numerous diseases and disorders, including cognitive deficits associated with CNS diseases and disorders.

Therapeutic thiophene-, furan-, and pyridine-fused azolopyrimidin-5-(6H)-ones

Therapeutic thiophene-, furan-, and pyridine-fused azolopyrimidin-5-(6h)-ones

Described herein are compounds and chemical entities of Formula I, methods of their synthesis, compositions comprising them, and their use in treating numerous diseases and disorders, including cognitive deficits associated with CNS diseases and disorders.

Substituted thiophene- and furan-fused azolopyrimidine-5-(6H)-one compounds

The invention provides a chemical entity of Formula (I) wherein R, R, R, R, X, and Y have any of the values described herein, and compositions comprising such chemical entities; methods of making them; and their use in a wide range of methods, including metabolic and reaction kinetic studies; detection and imaging techniques; radioactive treatments; modulating and treating disorders mediated by GlyT1 activity; treating neurological disorders, CNS disorders, dementia, neurodegenerative diseases, and trauma-dependent losses of function; treating stroke, including cognitive and motor deficits during stroke rehabilitation; facilitating neuroprotection and neurorecovery; enhancing the efficiency of cognitive and motor training, including animal skill training; and treating other disorders, including pain and alcohol-dependence. 

Substituted azetidinyl compounds as GlyT1 inhibitors

The invention provides a chemical entity of Formula (I), wherein R, R, R, R, Rand X have any of the values described herein, and compositions comprising such chemical entities; methods of making them; and their use in a wide range of methods, including metabolic and reaction kinetic studies; detection and imaging techniques; radioactive treatments; modulating and treating disorders mediated by GlyT1 activity; treating neurological disorders, CNS disorders, dementia, neurodegenerative diseases, and trauma-dependent losses of function; treating stroke, including cognitive and motor deficits during stroke rehabilitation; facilitating neuroprotection and neurorecovery; enhancing the efficiency of cognitive and motor training, including animal skill training; and treating other disorders, including pain and alcohol-dependence. 

Substituted 2,4,5,6-tetrahydropyrrolo[3,4-c]pyrazole and 4,5,6,7-tetrahydro-2H-pyrazolo[4,3-c]pyridine compounds as GlyT1 inhibitors

The present embodiments relate to compounds with physiological effects, such as the activation of hematopoietic growth factor receptors. The present embodiments also relate to use of the compounds to treat a variety of conditions, diseases and ailments such as hematopoietic conditions and disorders.

Hematopoietic growth factor mimetic small molecule compounds and their uses

Described herein are compounds and chemical entities of Formula (I), methods of their synthesis, compositions comprising them, and their use in treating numerous diseases and disorders, including cognitive deficits associated with CNS diseases and disorders.

Growing community of inventors

San Diego, CA, United States of America

Andrew Richard Hudson